
样式: 排序: IF: - GO 导出 标记为已读
-
Pathogens don't respect politicians: US federal disruption poses a new threat to global public health Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-06 Su Wang, Mark Harrington, Camilla S Graham, Louise O Downs, Nancy Kagwanja, Anthony O Etyang, Collins Iwuji, Thumbi Ndung'u, Benjamin C Cowie, Kenneth Kabagambe, Philippa C Matthews
No Abstract
-
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-06 Maria José Temido, Sailish Honap, Vipul Jairath, Severine Vermeire, Silvio Danese, Francisco Portela, Laurent Peyrin-Biroulet
Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding therapeutic armamentarium and the increasingly ambitious treatment targets have led to an increased use of advanced therapies and better outcomes. Nevertheless, many patients remain suboptimally treated and are at risk of disease progression, hospital admission, and surgery
-
Applying the estimand framework to inflammatory bowel disease clinical trials Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-03 Nurulamin M Noor, Maria Manuela Estevinho, Virginia Solitano, Yuhong Yuan, Brennan C Kahan, Vipul Jairath
No Abstract
-
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-03 Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, Chi-Yi Chen, Won-Mook Choi, Wonseok Kang, Gi-Ae Kim, Hyung Joon Kim, Yun Bin Lee, Jeong-Hoon Lee, Neung Hwa Park, So Young Kwon, Soo Young Park, Ji Hoon Kim, Gwang Hyeon Choi, Eun Sun Jang, Chien-Hung Chen, Yao-Chun Hsu, Ming-Jong Bair, Pin-Nan Cheng, Seungbong Han
BackgroundCurrent guidelines for chronic hepatitis B recommend antiviral therapy for individuals with non-cirrhotic chronic hepatitis B only if they have significant liver fibrosis or elevated alanine aminotransferase (ALT) concentrations. We aimed to assess the efficacy of early antiviral treatment in preventing serious liver-related adverse events in individuals with non-cirrhotic chronic hepatitis
-
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-03 Asgeir Johannessen
No Abstract
-
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-21 Aleksander Krag, Nikolaj Torp, Zobair M Younossi, Mads Israelsen
No Abstract
-
Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-16 Jochem C G Scheijmans, Jussi Haijanen, David R Flum, Wouter J Bom, Giana H Davidson, Corinne Vons, Arnold D Hill, Luca Ansaloni, David A Talan, Stefan T van Dijk, Sarah E Monsell, Saija Hurme, Suvi Sippola, Caroline Barry, Sorcha O'Grady, Marco Ceresoli, Ramon R Gorter, Gerjon Hannink, Marcel G Dijkgraaf, Paulina Salminen, Marja A Boermeester
BackgroundRandomised controlled trials (RCTs) have found antibiotics to be a feasible and safe alternative to appendicectomy in adults with imaging-confirmed acute appendicitis. However, patient inclusion criteria and outcome definitions vary greatly between RCTs. We aimed to compare antibiotics with appendicectomy for the treatment of acute appendicitis using individual patient data and uniform outcome
-
Antibiotics versus appendicectomy in acute appendicitis: delay is not denial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-16 Adewale O Adisa
No Abstract
-
Adjuvant aspirin therapy and colorectal cancer survival Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-14 Seohyuk Lee, Mingyang Song
No Abstract
-
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-14 John W K Chia, Eva Segelov, Yanhong Deng, Gwo Fuang Ho, Wei Wang, Shuting Han, Atul Sharma, Kefeng Ding, Gong Chen, Mark G Jeffery, Chee Kian Tham, Joong Bae Ahn, Louise Nott, Robert Zielinski, Tsu-Yi Chao, Tom van Hagen, Po-Li Wei, Fiona Day, Shaesta Mehta, Thomas Yau, Han Chong Toh
BackgroundAspirin is a simple, globally available medication that has been shown to reduce the incidence of colorectal cancer. We aimed to evaluate the safety and efficacy of aspirin in the secondary prevention of colorectal cancer. MethodsThis phase 3, randomised, double-blind, placebo-controlled trial was conducted at 66 centres across 11 countries and territories (ten in Asia-Pacific; one in the
-
The rise in early-onset colorectal cancer: now a global issue Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-10
No Abstract
-
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-10 Ziwei Gao, Wei Ye, Jingru Song
No Abstract
-
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-10 Xincheng Li, Ibrahim Ayada, Pengfei Li, Qiuwei Pan
No Abstract
-
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis – Authors' reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-10 George Kemble, Katharine Grimmer, Eduardo Bruno Martins, William McCulloch, Marie O’Farrell, Wen-Wei Tsai, Rohit Loomba
No Abstract
-
Bridging gaps in surgical care for neuroendocrine tumours: CUTNETs begins Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-10 Julie Hallet, Massimo Falconi, Stefano Partelli
No Abstract
-
Research in Brief Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-10 Holly Baker
Section snippets Guselkumab for moderately to severely active ulcerative colitisGuselkumab is a safe and efficacious treatment option for patients with moderately to severely active ulcerative colitis, according to the phase 3 QUASAR induction and maintenance studies. David T Rubin and colleagues randomly assigned patients with inadequate response or intolerance to conventional or advanced ulcerative
-
Primary intestinal lymphangiectasia Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-10 Rahael Ross
No Abstract
-
Ramadan intermittent fasting for patients with gastrointestinal and hepatobiliary diseases: practical guidance for health-care professionals Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-10 Muhammad Usman, Nasir Javed, Aida Jawhari, Nazim Ghouri, Salman Waqar, Fathima Shah, Saqib Ahmad, Ailsa Hart, Bilal Hameed, Mohammad Qasim Khan, Mohammad Farhad Peerally
Ramadan intermittent fasting can pose challenges and risks for some groups of patients. Based on a narrative literature review and our clinical expertise, we provide practical guidance for clinicians managing patients with gastrointestinal and hepatobiliary conditions who wish to fast during Ramadan. Following the established International Diabetes Federation and Diabetes and Ramadan International
-
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-09 Christopher J Black, Alexander C Ford
No Abstract
-
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-07 Raja Atreya, Markus F Neurath
No Abstract
-
Long-term VEDOKIDS results: implications for practice and research Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-06 Elizabeth A Spencer
No Abstract
-
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-06 Ohad Atia, Zivia Shavit-Brunschwig, Raffi Lev-Tzion, Ronen Stein, Efrat Broide, Darja Urlep, Jeffrey Hyams, Batia Weiss, Marina Aloi, Amit Assa, Konstantinos Gerasimidis, Ben Nichols, Richard K Russell, Dan Turner
BackgroundInfliximab and adalimumab are the only biologics thus far approved for paediatric patients with inflammatory bowel disease (IBD), so other biologics, such as vedolizumab, are prescribed off-label. Despite its frequent use, prospective data for vedolizumab treatment in children are available only for short-term induction outcomes. We aimed to evaluate the long-term efficacy and safety of maintenance
-
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-01-07 Prof Bruce E Sands MD, Prof Remo Panaccione MD, Prof Geert D'Haens MD, Prof Stefan Schreiber MD, Prof Vipul Jairath MD, Aaron DuVall MD, Prof Jaroslaw Kierkus MD, Michael Walczak MD, Snehal Naik PhD, Kye Gilder PhD, Beatriz Lindstrom PhD, Kathleen Ogilvie PhD, Prof William J Sandborn MD, Prof Severine Vermeire MD, Prof David T Rubin MD, Prof Laurent Peyrin-Biroulet MD, Prof Silvio Danese MD
Tamuzimod (VTX002) is a selective sphingosine 1-phosphate receptor 1 modulator in development for ulcerative colitis. We aimed to assess the safety and efficacy of tamuzimod in patients with moderately-to-severely active ulcerative colitis.
-
Widening access to recombinant zoster vaccination in IBD Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-19 James L Alexander, Nick Powell, Freddy Caldera, Nick Kennedy, Shahida Din
No Abstract
-
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-16 Anne Catrine Daugaard Mikkelsen, Kristoffer Kjærgaard, Anthony H V Schapira, Rajeshwar P Mookerjee, Karen Louise Thomsen
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects around 30% of the global population. Studies suggest that MASLD is associated with compromised brain health and cognitive dysfunction, initiating a growing interest in exploring the liver–brain axis mechanistically within MASLD pathophysiology. With the prevalence of MASLD increasing at an alarming rate, leaving a large proportion
-
The urgent need to end hepatitis B stigma and discrimination Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-17 Catherine Freeland, Jack Wallace, Su Wang, Prince Okinedo, Kenneth Kabagambe, Theobald Owusu-Ansah, Dee Lee, Charles Ampong Adjei, Thomas Tu, Chari Cohen
No Abstract
-
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-13 Julie Jemutai, Louise Downs, Motswedi Anderson, Chari Cohen, Janet Seeley, Binta Sultan, Joy Ko, Stuart Flanagan, Collins Iwuji, Rachel Halford, Oriel Fernandes, Peter Vickerman, Asgeir Johannessen, Philippa C Matthews
No Abstract
-
Action on ultra-processed foods needs robust evidence Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11
No Abstract
-
The promise of automated liver disease risk stratification in primary care Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Fredrik Åberg, Ville Männistö
No Abstract
-
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Kate Glyn-Owen, Ryan M Buchanan, Ahmed M Elsharkawy, Leah Avery, Stuart Flanagan, Heather Parsons, Ashwin Dhanda
No Abstract
-
Primary care diagnostic pathways for lower gastrointestinal symptoms Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Shahida Din, Astor Rodrigues, Pearl Avery, Neal Tucker, Debra Attwood
No Abstract
-
Retraction—Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11
Further to the Expression of concern The Lancet Gastroenterology & Hepatology issued in September 20241 for an Article presenting country, regional, and global estimates of lactose malabsorption,2 the Editors worked with the authors of the paper to determine whether further data included in the paper did not fully meet the study's stated eligibility criteria. Estimates for a substantial number of countries
-
Retraction—What is normal and abnormal in lactose digestion? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11
In this Comment,1 the authors cite and interpret data based on an Article we now know to be unreliable and that has now been retracted.2 The Committee on Publication Ethics advises that, in such circumstances, the linked Comment should also be retracted to avoid any misunderstanding among readers. We are therefore retracting this Comment.
-
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Abhishek Yadav
No Abstract
-
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Ming Duan, Yi Li
No Abstract
-
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 J Calvin Coffey, Yi Li, Dara Walsh, Tara M Connelly
No Abstract
-
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Matthias Kelm, Sven Flemming
No Abstract
-
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease – Authors’ reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Eline M L van der Does de Willebois, Willem A Bemelman, Christianne J Buskens
No Abstract
-
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Diana Coman, Robert Battat
No Abstract
-
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Yannick Hoffert, Marc Ferrante, Bram Verstockt, Erwin Dreesen
No Abstract
-
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis – Authors’ reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Christopher F D Li Wai Suen, Matthew C Choy, Danny Con, Peter De Cruz
No Abstract
-
Eligibility for antiviral therapy in Senegal according to 2024 WHO hepatitis B guidelines Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Bruce Shinga Wembulua, Adrià Ramírez Mena, Ndeye Fatou Ngom, Gilles Wandeler, Moussa Seydi
No Abstract
-
Correction to Lancet Gastroenterol Hepatol 2024; 9: 718–33 Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11
Janssen HLA, Lim Y-S, Lampertico P, et al. Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol 2024; 9: 718–33—In this Article, the label for previous other oral antiviral in figure 3B should have read 0·04; the label for previous
-
Correction to Lancet Gastroenterol Hepatol 2024; 9: 774–75 Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11
Click B, Holubar SD. Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand? Lancet Gastroenterol Hepatol 2024; 9: 774–75—In this Comment, the last sentence of the third paragraph should read “While previously described extended mesenteric excision approaches incorporate a high ligation of the ileocolic pedicle, van der Does de Willebois and colleagues assess a modified
-
ACG 2024 Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Bethany Gomersall
Section snippets Subcutaneous guselkumab for Crohn's diseaseInduction with subcutaneous guselkumab—a dual acting IL-23p19 subunit inhibitor—was safe and efficacious in patients with Crohn's disease according to the phase 3 GRAVITI study presented by Remo Panaccione (Calgary, AB, Canada). 347 patients with moderate-to-severe Crohn's disease with an inadequate response or intolerance to oral corticosteroids
-
The Liver Meeting 2024 Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Rob Brierley
Section snippets Semaglutide for MASHSemaglutide 2·4 mg once a week demonstrated significantly greater improvements in histology and fibrosis than did placebo in participants with metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis, according to data from the phase 3 ESSENCE trial. Although the trial is ongoing, Phil Newsome (London, UK) presented data from the prespecified
-
Research in Brief Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Holly Baker
Section snippets Mirikizumab for Crohn's diseaseMirikizumab, a monoclonal antibody targeting IL-23p19, shows promise for patients with moderately-to-severely active Crohn's disease, according to the VIVID-1 phase 3 trial. Marc Ferrante and colleagues randomly assigned patients who had a previous inadequate response, loss of response, or intolerance to one or more therapies to receive either mirikizumab
-
Shitbag: the story of a diagnosis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Cahal McQuillan
No Abstract
-
-
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Katrine P Lindvig, Katrine H Thorhauge, Johanne K Hansen, Maria Kjærgaard, Camilla D Hansen, Stine Johansen, Ellen Lyngbeck, Mads Israelsen, Peter Andersen, Katrine T Bech, Nikolaj Torp, Helle L Schnefeld, Sönke Detlefsen, Sören Möller, Isabel Graupera, Morten B Trelle, Steen Antonsen, Rebecca Harris, Line L Kårhus, Kirsten S Bjørnsbo, Maja Thiele
BackgroundClinically significant liver fibrosis is associated with future adverse events in patients with steatotic liver disease. We designed a software tool for detection of clinically significant liver fibrosis in primary care. MethodsIn this prospective cohort study, we developed and validated LiverPRO using six independent cohorts from Denmark, Germany, and England that included patients from
-
Rome Foundation and international neurogastroenterology and motility societies’ consensus on idiopathic gastroparesis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Jolien Schol, I-Hsuan Huang, Florencia Carbone, Luis Maria Bustos Fernandez, Guillaume Gourcerol, Vincent Ho, Geoffrey Kohn, Brian E Lacy, Aurelio Lopez Colombo, Hiroto Miwa, Baha Moshiree, Linda Nguyen, Greg O’Grady, Kewin T H Siah, Vincenzo Stanghellini, Jan Tack
To establish a consensus on the definition and management of idiopathic gastroparesis, international experts (selected by neurogastroenterology and motility societies and initiated by the Rome Foundation) devised 144 statements using the Delphi method, with at least 80% agreement required. This consensus defined idiopathic gastroparesis as the presence of symptoms associated with delayed gastric emptying
-
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-11 Jacob J Gries, Jeffrey V Lazarus, Paul N Brennan, Mohammad S Siddiqui, Giovanni Targher, Chim C Lang, Salim S Virani, Carl J Lavie, Scott Isaacs, Juan Pablo Arab, Kenneth Cusi, Chayakrit Krittanawong
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a public health threat as it affects approximately 38% of the adult population worldwide, with its prevalence rising in step with that of obesity and type 2 diabetes. Beyond the implications of MASLD for liver health, it is also associated with cardiovascular and vascular dysfunction. Although the many shared risk factors
-
Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-12 Andrea Lindfors MD, Rickard Strandberg PhD, Prof Hannes Hagström MD PhD
International guidelines suggest screening for advanced fibrosis due to metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes, but how to implement these guidelines in clinical care remains unclear. We hypothesise that examination with VCTE could be implemented simultaneously with retina scanning with a high acceptance rate in people with type 2 diabetes.
-
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-12 Stefano Ciardullo, Gianluca Perseghin
No Abstract
-
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-09 Andreas A Schnitzbauer
No Abstract
-
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-09 Guillaume Martel MD, François Martin Carrier MD, Christopher Wherrett MD, Tori Lenet MD, Katlin Mallette MD, Karine Brousseau MSc, Leah Monette MSc, Aklile Workneh MSc, Monique Ruel MSc, Elham Sabri MSc, Heather Maddison MLT, Melanie Tokessy MLT, Patrick B Y Wong MD, Prof Franck Vandenbroucke-Menu MD, Luc Massicotte MD, Michaël Chassé MD, Yves Collin MD, Michel-Antoine Perrault MD, Élodie Hamel-Perreault
Blood loss and subsequent red blood cell transfusions are common in liver surgery. Hypovolaemic phlebotomy is associated with decreased red blood cell transfusion in observational studies. This trial aimed to investigate whether hypovolaemic phlebotomy is superior to usual care in reducing red blood cell transfusions in patients undergoing liver resection.
-
International consensus statement on microbiome testing in clinical practice Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-05 Serena Porcari MD, Benjamin H Mullish MD, Francesco Asnicar PhD, Prof Siew C Ng MD, Prof Liping Zhao PhD, Richard Hansen MD, Prof Paul W O'Toole PhD, Prof Jeroen Raes PhD, Prof Georgina Hold PhD, Lorenza Putignani PhD, Christian Lodberg Hvas MD, Georg Zeller PhD, Prof Omry Koren PhD, Hein Tun PhD, Mireia Valles-Colomer PhD, Maria Carmen Collado PhD, Monika Fischer PhD, Jessica Allegretti MD, Tariq
There is growing interest in the potential exploitation of the gut microbiome as a diagnostic tool in medicine, but evidence supporting its clinical usefulness is scarce. An increasing number of commercial providers offer direct-to-consumer microbiome diagnostic tests without any consensus on their regulation or any proven value in clinical practice, which could result in considerable waste of individual
-
Targeting socioeconomic inequity to reduce liver disease related to alcohol use Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-04 Charlotte Probst, Carolin Kilian
No Abstract
-
Does filgotinib work for Crohn's disease? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-02 Mark Andrew Ainsworth
No Abstract
-
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-12-02 Prof Séverine Vermeire MD, Stefan Schreiber MD, David T Rubin MD, Geert D'Haens MD, Walter Reinisch MD, Mamoru Watanabe MD, Rajiv Mehta MD, Xavier Roblin MD, Ian Beales MD, Piotr Gietka MD, Toshifumi Hibi MD, Ihor Hospodarskyy MD, Timothy Ritter MD, Mark C Genovese MD, Paul Kwon MD, Eva Santermans PhD, Franck-Olivier Le Brun MSc, Rahul Barron MD, Tomasz Masior MD, Silvio Danese MD
There is a need for efficacious therapies for patients with Crohn's disease that are better tolerated and more durable than available treatments. We aimed to evaluate the efficacy and safety of filgotinib, an oral Janus kinase 1 preferential inhibitor, for treating Crohn's disease.